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Abstract
Preclinical studies showed that the allogeneic tumor cell line RCC-26 displayed natural immunogenic potential
that was enhanced through expression of CD80 costimulatory molecules and secretion of interleukin-2. Here we
report the study of RCC-26=CD80=IL-2 cells in a phase 1 vaccine trial of renal cell carcinoma patients with
metastatic disease (mRCC). Fifteen patients of the HLA-A*0201 allotype, with at least one metastatic lesion, were
included. Irradiated vaccine cells were applied in increasing doses of 2.5, 10, and 40106 cells over 22 weeks.
Primary study parameters included safety and toxicity. Sequential blood samples were analyzed by interferon-g
enzyme-linked immunospot assays to detect tumor antigen-associated (TAA) effector cells. The vaccine was well
tolerated and the designated vaccination course was completed in 9 of 15 patients. Neither vaccine-induced
autoimmunity nor systemic side effects were observed. Delayed-type hypersensitivity skin reactions were de-
tected in 11 of 12 evaluated patients and were particularly strong in patients with prolonged survival. In parallel,
vaccine-induced immune responses against vaccine or overexpressed TAA were detected in 9 of 12 evaluated
patients. No tumor regressions occurred according to RECIST (Response Evaluation Criteria in Solid Tumors)
criteria; however, median time to progression was 5.3 months and median survival was 15.6 months, indicating
substantial disease stabilization. We conclude that vaccine use was safe and feasible in mRCC. Clinical benefits
were limited in these patients with advanced disease; however, immune monitoring revealed vaccine-induced
responses against multiple TAAs in the majority of study participants. These results suggest that this vaccine
could be useful in combination therapies and=or minimal residual disease.
Introduction
Up to 30% of patients with renal cell carcinoma (RCC)have metastatic disease at the time of diagnosis, and
metastases develop metachronously in 20–40% of patients
undergoing partial or radical nephrectomy for clinically
localized tumors ( Janzen et al., 2003). Targeted molecular
therapies have become available that can slow tumor pro-
gression, offering new hope for patients with metastatic RCC
(mRCC). These therapies are directed primarily toward in-
terruption of signaling pathways that foster angiogenesis
(Longo et al., 2007). Although initial retardation of tumor
growth is achieved with several new classes of angiogenesis
inhibitors and some tumors show regression in imaging, most
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patients with RCC develop therapy resistance over time
(Sosman et al., 2007). Therefore, there is still an important
therapeutic need for patients with metastatic disease.
Among patients with cancer, those with RCC show some
of the most favorable responses to immunotherapy (Kim
et al., 2003; Motzer, 2003). Cancer vaccines represent one
treatment strategy to exploit this immunological potential
because there is evidence that immunization against tumors
can reduce or even eliminate some tumors and induce long-
lasting T cell memory responses with a capacity to control
tumor relapse. Nevertheless, vaccine treatment alone has
shown clinical benefit in only a small number of patients
with mRCC (Simons et al., 1997; Frankenberger et al., 2005b;
Schendel, 2007). Thus, future treatment strategies that com-
bine targeted molecular therapies with low-toxicity vaccina-
tion might enhance the development of effective immune
responses and improve the long-term perspectives of patients
with advanced disease.
Various vaccine strategies have been developed to induce
antitumor T cell responses (Pardoll, 1998), several of which
have been applied in patients with mRCC (Frankenberger
et al., 2005b; Schendel, 2007). One approach is to use autol-
ogous gene-modified tumor cells as vaccines, introducing
immunologically relevant genes to enhance tumor cell im-
munogenicity (Mach and Dranoff, 2000). The first phase 1
trial in RCC implementing this strategy, through introduc-
tion of the gene encoding granulocyte-macrophage colony-
stimulating factor (GM-CSF) into autologous tumor cells,
demonstrated clinical benefit in several patients (Simons et al.,
1997) and induction of specific T cell immunity (X. Zhou et al.,
2005). More recently, an autologous gene-modified tumor
cell vaccine that expressed the costimulatory molecule CD80
was tested in patients with mRCC in combination with
systemic interleukin (IL)-2 (Antonia et al., 2002; Fishman et al.,
2008). No severe toxicity was associated with these vaccines.
However, strong limitations in feasibility and high costs
are incurred with the production of individualized gene-
modified tumor cell vaccines. Generic vaccines that could be
applied to many patients would reduce development time
and costs and enable treatment of more patients.
We developed an allogeneic gene-modified RCC vaccine
based on a well-characterized tumor cell line that showed
improved immunogenicity through expression of CD80 and
IL-2 (Frankenberger et al., 2005a). The original cell line (RCC-
26) (Schendel et al., 1993) was derived from an HLA-A*0201-
positive patient with stage I disease (pT1pN0M0G2) in whom
only a single brain metastasis appeared after nephrectomy,
following a disease-free interval of 9 years. The RCC-
26=CD80=IL-2 vaccine was tested in a clinical phase 1 trial to
evaluate safety and feasibility with stage IV mRCC patients
matched for the HLA-A*0201 allotype. Furthermore, the
ability of vaccination to induce specific T cell reactivity was
analyzed with enzyme-linked immunospot (ELISPOT) assays
to detect T cell responses to vaccine cell lysates as well as to
surrogate peptides that were derived from tumor-associated
antigens (TAAs) that are overexpressed in mRCC lesions.
Materials and Methods
Patients
Between September 2003 and August 2006, 15 patients
with histologically proven clear-cell RCC and at least one
evaluable metastasis were enrolled in the clinical study. This
study is registered with the German Somatic Gene Transfer
Clinical Trial Database (DeReG [Deutsches Register fu¨r so-
matische Gentransferstudien], reference number 47). Poten-
tial study patients were screened for the HLA-A*0201
allotype first by serological typing using flow cytometry,
followed by genotyping with an HLA-A*02-specific poly-
merase chain reaction (PCR), as described previously (Gatz
et al., 2000). The PCR product encompassing exons 2 and 3
was subsequently sequenced. Only patients with an HLA-
A*0201 subtype were finally included in the clinical study.
Further inclusion criteria were good performance status
(Eastern Cooperative Oncology Group [ECOG] score, 0 or 1),
no surgery during the previous 4 weeks, no systemic anti-
tumoral therapy during the previous 12 weeks, no evidence
of autoimmune disease, and no use of systemic immune-
modulatory therapies (e.g., corticosteroids). Initial staging on
the basis of computer tomography (CT) and bone scan was
performed 1 week before the first vaccination. All patients
gave written informed consent before entering the study. The
trial protocol was approved by the local ethics committee
and the good manufacturing practice (GMP)-certified vac-
cine production was approved by the responsible national,
state, and local authorities.
Vaccination and study schedule
The genetically modified RCC-26=CD80=IL-2 vaccine
was generated as described previously (Frankenberger et al.,
2005a). The cells were expanded under GMP conditions and
stored in the gas phase of liquid nitrogen in ampoules with
2.5106 or 10106 cells. For safety reasons, all cryopreserved
vaccine aliquots were irradiated (120Gy) in one batch under
controlled conditions. The vaccine cells were thawed imme-
diately before patient application and given by intradermal
injection into the inguinal region. Graded doses of cells were
applied up to 10 times over a 22-week period. The vaccination
schedule was as follows: 2.5106 cells at weeks 1, 2, 4, and 6;
10106 cells at weeks 8, 10, 12, and 14; and 40106 cells at
weeks 18 and 22. Clinical examination and routine blood
checks were performed at every visit. Patients were assessed
for signs of autoimmune disease by measurement of thyroid
hormones and pancreatic enzymes, screening for anti-nuclear
antibodies, as well as monitoring of rheumatoid factor and
complement factors. Blood samples for immune monitoring
were taken at weeks 1, 6, 14, 22, and 36. Restaging on the basis
of CT was performed at weeks 8, 18, 24, and 36. Patients were
withdrawn from the study on evidence of tumor progres-
sion according to the Response Evaluation Criteria in Solid
Tumors (RECIST) (Therasse et al., 2000). In four patients, the
lowest vaccine dose (2.5106 cells) was omitted and vacci-
nation was initiated with a dose of 10106 cells.
Delayed-type hypersensitivity testing
We assessed the patients for delayed-type hypersensitivity
(DTH) reactions to challenge with irradiated vaccine cells
after 4, 8, and 10 vaccinations at weeks 6, 14, and 22, re-
spectively. Skin tests were performed by intradermal injec-
tion of 2.5106 cells at a site distant from the vaccination sites
in the inguinal region. A DTH reaction evaluated 48 hr
postchallenge was judged as positive if induration or ery-
thema of at least 10mm was observed.
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Microarray analysis of TAA expression in tumors
and RCC-26 cells
Tissue samples from 32 patients with clear-cell RCC me-
tastases were collected, snap-frozen, and stored in liquid
nitrogen after written informed consent had been obtained.
Cryostat sections were made and laser microdissection was
used to isolate tumor cells (PALMMicroBeam; Zeiss, Munich,
Germany). Total RNA was extracted from these cells and
also from RCC-26 cells (RNeasy micro kit; Qiagen, Hilden,
Germany). RNA integrity was tested by capillary electro-
phoresis (2100 Bioanalyzer; Agilent, Santa Clara, CA).
Thereafter, RNA amplification and hybridization on oligo-
nucleotide microarrays (GeneChip Human Genome U133
Plus 2.0 array; Affymetrix, Santa Clara, CA) were performed
with the manufacturer’s reagents in accordance with the
standard protocol. Normalized expression values were cal-
culated for every transcript, using dChip software (Li and
Wong, 2001) (A. Buchner, unpublished data). Expression
levels of survivin, cyclin D1, adipophilin, and c-Met were
quantified by quantitative real-time polymerase chain reac-
tion (qRT-PCR) according to methods described elsewhere
(Frankenberger et al., 2005a). Primer sequences are available
on request.
Immune monitoring
Blood samples from the patients were drawn at study
weeks 1, 6, 14, 22, and 36, and peripheral blood mononu-
clear cells (PBMCs) were isolated by density gradient cen-
trifugation using Leucosep (Greiner Bio-One, Frickenhausen,
Germany) and cryopreserved. Additional samples from five
patients were taken on day 15 after the last (tenth) vaccination
and samples were available from two patients during longer
follow-up. For interferon (IFN)-g ELISPOT assays, the cells
were thawed, washed with CTL Wash supplement medium
(Cellular Technology, Cleveland, OH) plus Benzonase nu-
clease (Novagen Merck Biosciences, Darmstadt, Germany),
rested, and seeded at 1.5105 cells in quadruplicate on
antibody-precoated polyvinylidene difluoride (PVDF) plates
(Mabtech, Nacka, Sweden). The PBMCs were stimulated
directly with selected peptides (each peptide, 5mg=ml) in
serum-free culture medium (CTL Test medium; Cellular
Technology), supplemented with CD28 (1mg=ml; BD Bio-
sciences, San Jose, CA) and recombinant IL-2 (Proleukin,
2U=ml; Chiron, Emeryville, CA). The assays were developed
as previously described (Brill et al., 2007). Spots were counted
with AID reader system ELR03 with software version 4.0
(Autoimmun Diagnostika [AID], Strassberg, Germany) and
controlled by human audit. The performance of the assay was
externally validated by participation in the immune assay
proficiency panels of the international Cancer Vaccine Con-
sortium at the Cancer Research Institute, New York, USA
( Janetzki et al., 2008) and the Association for Immunotherapy
of Cancer (CIMT), Mainz, Germany (Britten et al., 2008). De-
finition of positive responses was based on proposed inter-
national criteria (Britten et al., 2008; Janetzki et al., 2008).
Surrogate peptides for immune monitoring were selected
from sequences of TAAs shown to be overexpressed in
metastatic RCC lesions and=or the vaccine cells, using HLA-
A*0201 motif-based epitope predictions available on the web
(http:==www.syfpeithi.de), or as published in the literature.
Peptides specific for the followingantigenswereused: survivin
(ELTLGEFLKL95–104, TLPPAWQPFL5–14 [Schmitz et al., 2000]),
heteroclitic survivin-related peptide (LMLGEFLKL69–104
[Otto et al., 2005], EKVRRAIEQL129–138), cyclin D1
(LLGATCMFV101–109, RLTRFLSRV228–236 [Sadovnikova et al.,
1998]), adipophilin (SVASTITGV129–137, TLLSNIQGV327–335
[Weinschenk et al., 2002], VMAGDIYSV348–356), c-Met proto-
oncogene (YVDPVITSI654–662, VLAPGILVL6–14, GLIAGVV-
SI31–39 [Weinschenk et al., 2002]), regulator of G protein sig-
naling (RGS-5) (LAALPHSCL5–13 [Kruger et al., 2005],
ILLQKPDSV25–33, KLLQNNYGL67–75), apolipoprotein L
(ALADGVQKV176–184 [Weinschenk et al., 2002], FLGENIS-
NFL242–251 [Flad et al., 1998]), mucin (MUC)-1 (STAPP-
VHNV130–138, LLLLTVLTV12–20 [Apostolopoulos et al., 1997;
Brossart et al., 1999]), KIAA0367 (PRUNE2) (ALFDGDPHL1–9
[Weinschenk et al., 2002]), oncofetal antigen (OFA) (LLLAAR-
AIV60–68, LAARAIVAI58–66 [Siegel et al., 2003]), human telo-
merase reverse transcriptase (hTERT) (ILAKFLHWL540–548
[Vonderheide et al., 1999], RLVDDFLLV865–873 [Minev et al.,
2000]), vascular endothelial growth factor (VEGF) (LLSWVH-
WSL4–12, ALLLYLHHA13–21), NY-ESO-1 (SLLMWITQC157–165,
SLLMWITQCFL157–167 [Jager et al., 1998]), Her2=neu (ALCR-
WGLLL5–13 [Kawashima et al., 1998], HLYQGCQVV48–56
[Scardino et al., 2001]), melanoma-associated antigen (MAGE)-
A1 (KVLEYVIKV278–286 [Pascolo et al., 2001]), MAGE-A3
(FLWGPRALV271–279 [van der Bruggen et al., 1994; M. Zhou
et al., 2005], KVAELVHFL112–120 [Kawashima et al., 1998]),
MAGE-A6 (ALSRKVAKL108–116), MAGE-A3=A6 (TLVEVTL-
GEV44–53), and Wilms’ tumor suppressor antigen (WT-1)
(RMFPNAPYL126–134 [Oka et al., 2000]).
Peptide synthesis and vaccine cell lysate preparation were
performed as described previously (Brill et al., 2007). An ir-
relevant peptide for Bcr3=Abl2 [SSKALQRPV926–934 (Yotnda
et al., 1998)] was used as a negative control and the HLA-A2
CEF (human cytomegalovirus, Epstein–Barr virus, and in-
fluenza virus) peptide pool (CMVpp65, NLVPMVATV495–503;
EBV-BMLF1, GLCTLVAML280–288; EBV-LMP-2, CLGGLLT-
MV426–434; influenza M1 protein, GILGFVFTL58–66; and in-
fluenza RNA polymerase PA, FMYSDFHFI46–54), with 0.2mg
of each peptide per well, was used as a positive control
(PANATecs, Tu¨bingen, Germany).
Statistics
Time to progression and tumor-specific survival were
analyzed by the Kaplan–Meier method.
Results
Characteristics of study patients
Table 1 summarizes the characteristics of the patients en-
rolled in this study. There were more male than female
participants (11 males vs. 4 females) and the patients ranged
in age from 39 to 78 years (mean, 59 years) at study entry. In
nine patients, the time from first diagnosis to disease pro-
gression and study entry was 2 years or less. This interval
was 3–12 years for six patients, with three patients showing
disease progression only after 8, 11, and 12 years. The TNMG
classification of the tumors was variable. At the time of en-
rollment, the majority of patients had multiple metastases at
two or more sites, revealing their advanced states of disease.
All but two patients had lung lesions and the second most
prevalent site of metastasis was the lymph node. According
to the study protocol, all patients had good performance
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status (ECOG scores of 0 or 1). Patients were also evalu-
ated for prognosis according to the Palmer scoring criteria
(Palmer et al., 1992). Seven patients had good scores of 0 or 1,
whereas eight patients were classified with poor scores of 2
or 3, according to the designated criteria of performance
status, number of metastatic sites, and time from first diag-
nosis to study entry.
The primary tumors of all patientswere surgically removed
at the time of primary tumor diagnosis. Ten patients were
treated subsequently with some form of immunotherapy,
with the majority receiving cytokine therapy in the form of
subcutaneous IFN-a and IL-2, with or without 5-fluorouracil.
Three patients received anti-G250 antibody therapy and one
patient was treated with the multi-tyrosine kinase inhibitor
sorafenib, which was stopped after only a few days because of
severe skin reactions. Two patients were included in previous
vaccine trials using either tumor lysate-pulsed dendritic cells
(Holtl et al., 2005) or a pool of HLA-A2-restricted, tumor-
associated peptides.
Vaccination schedule and clinical outcome
Figure 1A shows the vaccine dose and time schedule as
well as points of clinical restaging, measurement of DTH
reactions, and acquisition of samples for subsequent immune
monitoring. The vaccination course for individual patients
and various parameters of clinical outcome are summarized
in Table 2. There was no difference in outcome between the
four patients (MR-6, MR-7, MR-8, and MR-9) who received
the short vaccination schedule that excluded the four low-
dose vaccinations and the remaining patients. Patient MR-3
died 1 week after the second vaccination but no causal re-
lationship was found between vaccination and death in this
elderly patient. Patient MR-11 died in study week 17, 3
weeks after receipt of the eighth vaccine application. This
patient had stable disease at the previous restaging accord-
ing to RECIST criteria, and there was no evidence of a causal
relationship with vaccination.
No remissions were observed in any patient according to
RECIST criteria. In various patients tumor progression oc-
curred at various sites, including the appearance of new
lesions in the brain, bone, liver, adrenal glands, and lymph
nodes in various individuals. Interestingly, progression of
lung metastases was detected in only one instance and this
patient showed a slow progression course (MR-4). At the
end of the 36-week study period, 60% of the patients were
alive. The median time to progression was 5.3 months
(Fig. 1B). The median tumor-specific survival time was 15.6
months (Fig. 1C) and two patients are still alive to date, 24
and 35 months after study entry.
Analysis of safety and toxicity
The vaccine was well tolerated and no patient was with-
drawn from the study because of side effects. The most
common side effects noted were erythema, induration, and
pruritus for a few days at the vaccine injection sites or DTH
challenge sites. In most cases these responses occurred only
after four or more vaccine applications. No local or systemic
therapy was needed for treatment of adverse events in any
study patient. In most cases, routine blood parameters (e.g.,
differential blood count, creatinine, electrolytes, and trans-
aminases) showed no significant changes during the entire
study period. Four patients (MR-9, MR-13, MR-14, and MR-
15) showed transient increases in a-amylase and=or lipase,
reaching up to 5-fold upper reference levels, with complete
normalization after several weeks. The earliest detection of
enzyme increase was after the fifth vaccination, when the
vaccine dose was increased to 10106 cells and vaccination
applications were given at 2-week intervals (Fig. 1D). Further
increases were not detected when the highest vaccine doses
were applied at 4-week intervals. The enzyme increases were
Table 1. Patient Characteristics
ID Gender
Age (years)
at first
diagnosis
Age (years)
at study
entry TNMG
Prognostic
scorea
Therapy before
study entry
Site(s) of
metastases
MR-1 M 39 40 pT2pN0M0G2 2 — Lung, bone
MR-2 M 65 67 pT2pN0M1G3 1 Cytokine,b G250c Lung, LN
MR-3 M 77 78 pT3aNxM1G2 2 — Lung
MR-4 F 66 68 pT3bpN0M1G2 1 Cytokine, G250 Lung, LN, adrenal gland
MR-5 M 60 62 pT3bpN0M1G2 1 Cytokine Lung
MR-6 M 61 61 pT3bNxM1G2 2 — Bone
MR-7 M 52 64 pT2pN0M0G2 1 — Pleura, LN, local recurrence
MR-8 M 32 43 pT2pN0M0G2 2 Cytokine Lung, adrenal gland
MR-9 F 67 68 pT1pN0M1G2 2 Cytokine Lung, pancreas
MR-10 F 60 65 pT2NxM0G1 0 Sorafenib Lung
MR-11 M 46 49 pT3bNxM1G2 2 G250 Lung, LN, spinal cord
MR-12 F 47 48 pT1pN2M1G3 3 Cytokine Lung, LN, bone
MR-13 M 50 54 pT1pN0M0G2 1 Vaccined Lung, LN, brain
MR-14 M 61 61 pT3apN0M1G3 2 Vaccine Lung, LN, adrenal gland
MR-15 M 50 58 pT2NxM1G2 1 Cytokine Lung, LN
Abbreviations: F, female; LN, lymph node; M, male; TNMG: tumor size, node involvement, metastasis, grade.
aScore from 0 (very low risk) to 3 (high risk); based on performance status, number of metastatic sites, and time from first diagnosis to
study entry (Palmer et al., 1992).
bCytokine: interferon-a, interleukin-2, 5-fluorouracil.
cG250: monoclonal antibody directed against carbonic anhydrase-9.
dVaccine: multipeptide vaccine or dendritic cell vaccine.
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FIG. 1. (A) Time schedule of the vaccine study. (B) Kaplan–Meier plot of time to progression, with a median of 5.3 months.
(C) Kaplan–Meier plot of tumor-specific survival, with median of 15.6 months. (D) Pancreatic enzyme changes during
vaccination. An example is shown of the transient increases in amylase and lipase during the vaccination course of patient
MR-14. The values are given as units per liter on the y axis over the study course in weeks on the x axis. The arrows indicate
the times of vaccination at the three dose levels.
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not accompanied by clinical symptoms and additional clinical
examination revealed no evidence of pancreatitis. Moreover,
no patient showed evidence of clinically relevant autoimmu-
nity, as assessed by standard laboratory parameters.
Immunological assessment of vaccine responses
in vivo
DTH reactions were detected in 11 of 12 evaluated pa-
tients after challenge with vaccine cells applied intradermally
in the inguinal region at weeks 6, 14, and 22. Furthermore,
most patients reported similar reactions at the sites of regular
vaccine injections, first appearing after the receipt of at least
three vaccine applications. The DTH challenge reactions
were first assessed after patients had received four vaccine
applications. Subsequent DTH challenge reactions increased
in size and intensity with further vaccination. Reactions al-
ways disappeared within a few days and did not require
medical intervention. Patient MR-6 failed to develop a DTH
response even though he received four vaccine applications.
Immune monitoring of lymphocyte responses ex vivo
Sequential patient peripheral blood samples (see Fig. 1A)
were obtained throughout the study period and IFN-g ELI-
SPOT analyses were performed to compare lymphocyte re-
sponses to a variety of stimuli before and after vaccination.
These studies were performed with various numbers of
samples from 12 patients, dependent on the course of vac-
cination completed by each individual. Data were not
available for patients MR-3, MR-8, and MR-12, who did not
reach the time point for obtaining the first immune moni-
toring sample after four vaccine applications at either the low
or intermediate cell doses (see Table 2 and Fig. 1A).
To determine the general capacity of patient PBMCs to
respond to antigenic stimulation, IFN-g responses were as-
sayed with a pool of HLA-A2-restricted viral peptides de-
rived from proteins of cytomegalovirus, Epstein–Barr virus,
and influenza virus, designated as the CEF peptide pool.
Most HLA-A2 healthy donors have some memory T cells
that respond to at least one of the peptides included in this
Table 2. Vaccine Doses Delivered and Clinical Outcome
ID
2.5106
cells
10106
cells
40106
cells
Time to
progression (weeks)
Site(s) of
progression
Survival time
(weeks)
Survival status at
study end
MR-1 4 1 — 7 Bone, braina 31 DOD
MR-2 4 4 2 23 Pleura, bonea 79 DOD
MR-3 2 — — — — 2 Dead, not related to therapy=disease
MR-4 4 4 2 35 Lung 68 DOD
MR-5 4 4 2 7 LN,a adrenal glanda 76 DOD
MR-6 — 4 — 6 Bone 18 DOD
MR-7 — 4 2 28 Pleura, livera 84 DOD
MR-8 — 3 — 6 Peritoneum 13 DOD
MR-9 — 4 2 39 Pancreas, livera 79 DOD
MR-10 4 4 2 23 Braina 55 DOD
MR-11 4 4 — 7b — 17 Dead, not related to therapy=disease
MR-12 4 — — 5 Bone 8 DOD
MR-13 4 4 2 33 Brain 104 Alive
MR-14 4 4 2 35 LN 107 DOD
MR-15 4 4 2 131b — 151 Alive
Abbreviations: DOD, dead of disease.
aNew metastases.
bStable disease at this time.
FIG. 2. Monitoring of immune responses by ELISPOT to vaccine lysate and surrogate peptides and peptide pools. (A) IFN-g
ELISPOT results of PBMC samples obtained pre- and postvaccination of 12 patients after stimulation with vaccine cell lysates.
Increased immune responses were detected in nine patients after vaccination: median, mean, and range are given as spots per
1.5105 PBMCs obtained before the start of vaccination (pre) and the maximal response detected at any time point after at
least four vaccine applications (post). Delta (D) values represent differences between prevaccine responses and postvacci-
nation responses, using the highest response measured at any time point after at least four vaccine applications. (B) Re-
sponses to peptides derived from the candidate TAAs designated in Fig. 3. Tested were two pools of peptides (pools B and D)
and four single peptides, giving a total of six stimuli that were used to activate patient PBMCs obtained pre- and post-
vaccination. Summarized are the numbers of patients whose PBMCs showed positive ELISPOT responses to none or to one to
six of the various pools=peptides at any time after four vaccine applications as compared with prevaccination values. The
actual ELISPOT data are given in Table 3. (C) Numbers of patients responding to the four single peptides compared with the
levels of TAA overexpression in the vaccine cells, as quantified by qRT-PCR. TAA overexpression (mean value) is based on
crossing-point analysis of the vaccine RCC-26=CD80=IL-2 cells as compared with a pool of five commercially obtained RNAs
of normal kidney tissue as follows: þþ, 16- to 63-fold; þþþ, 64- to 256-fold; þþþþ, >256-fold. ADFP, adipophilin (adipose
differentiation-related protein). (D and E) Representative examples of ELISPOT results of patients MR-2 and MR-4 to (D) four
single peptides and (E) peptide pools B and D. Data are presented as numbers of IFN-g-secreting cells (spots) per 1.5105 cells
(y axis) over the study week course (x axis).
‰
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pool (Currier et al., 2002). Responses to CEF peptides were
detected in prevaccination samples of all 12 patients (data
not shown). Positive responses to CEF peptides were also
detected in 37 of 38 patient blood samples obtained post-
vaccination, indicating that overt immune suppression ca-
pable of blocking all capacity for memory immune responses
did not occur despite disease progression in most patients.
However, five of nine patients evaluated 22 or 36 weeks after
study entry did show substantial decreases in the magnitude
of their CEF responses (data not shown). This, however, was
not indicative of a shorter period of time to progression.
Vaccine cell lysates were used to determine immune
reactivity as a whole to vaccine-associated determinants
(Fig. 2A). Interestingly, several patients showed substantial
responses to vaccine lysates in PBMCs obtained before vac-
cination. Nevertheless, the median and mean ELISPOT re-
sponses in nine patients increased substantially in the
postvaccination samples in comparison with prevaccination
levels. The median and mean differences between the pre-
and postvaccination responses of the nine immune re-
sponders were determined and depicted as delta (D) values.
This revealed a mean change of 177 spots, with a median of
120 in the nine responding patients (Fig. 2A).
To determine whether TAA-specific responses were in-
duced as a result of vaccination, ELISPOT responses were
tested with a panel of surrogate peptides derived from TAAs
that are prevalent in RCC or other tumors. The TAAs used
for this analysis were tested for their prevalence and ex-
pression levels, using a microarray analysis of 32 mRCC le-
sions derived from a local tissue biorepository. RCC-26 cells
were also included in this analysis (Fig. 3). All but one of the
selected TAAs were expressed in the majority of tumor
samples. Several TAAs were expressed in metastatic lesions
but were not detected in RCC-26 cells. Nevertheless, they
were included for future studies assessing epitope spreading.
Several TAAs that were negative or poorly expressed in
tumor samples and not expressed in RCC-26 cells were in-
cluded as negative controls. It was not possible to perform
similar array studies with patient tumors because the patients
were recruited from throughout Germany and most entered
the study several years after their primary diagnosis.
Therefore, cryopreserved archival material was not available
and for ethical reasons the protocol did not allow new bi-
opsies to be made from the lung, bone, or liver metastases of
these patients with advanced disease. Nevertheless, the
analysis of metastatic RCC lesions obtained from the local
tissue biorepository showed broad expression of most TAA
candidates in a representative mRCC patient population.
The immune-monitoring peptides derived from these 17
TAAs all carried anchor residues that allowed them to be
presented by autologous HLA-A2 molecules (see Materials
and Methods). Because of the high number of peptides to be
evaluated, pools B and D, which contained multiple pep-
tides, were created. Subsequent to vaccination, the responses
of individual patients varied over time and various patients
showed prominent responses to the two pools. Represen-
tative responses are summarized in Table 3, in which pre-
vaccine values are juxtaposed to the strongest recorded
responses detected at any time point postvaccination. An
HLA-A2-restricted peptide derived from the Bcr=Abl fusion
protein (Yotnda et al., 1998) was used as a background
control and only low numbers of spots (median, 0 spots;
range, 0 to 29 spots) were detected in pre- and postvacci-
nation samples (data not shown). T cell responses were also
measured against four single peptides, survivin, cyclin D1,
adipophilin (adipose differentiation-related protein [ADFP]),
and c-Met, which were shown previously by others to be
associated with T cell reactivity in patients with RCC
FIG. 3. Expression of tumor-associated antigens in metastatic RCC lesions and RCC-26 cells. Given are percentages of
samples positive for selected candidate antigens in a panel of 32 metastatic RCC lesions and normalized levels of antigen
expression in microdissected tumor cells from the metastatic lesions and in RCC-26 cells as determined by microarray
analysis. The scale for the model-based expression index is as follows: –, no expression; þ, <100; þþ, 100–999; þþþ, 1000.
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(Stevanovic, 2002). Seven of 12 patients showed responses to
either the single peptides and=or the pools, with all seven
immune responders showing responses to two or more
peptides=pools that were greater than 2-fold compared with
prevaccination values (Fig. 2B). It should be noted that most
patients showed substantial prevaccination responses to one
or both pools and several of the single peptides, indicating
that their PBMCs contained effector memory cells. The TAAs
from which the four single peptides were derived showed
variations in mRNA expression levels in the vaccine cells, but
this did not impact on the number of patients capable of
responding to the individual peptides (Fig. 2C). The time
courses of responses to the single peptides and pools B and D
are illustrated for two representative patients (Fig. 2D and E).
In general, responses to the individual stimuli (pools or
single peptides) showed similar patterns of increase or de-
crease throughout the vaccine schedule.
Discussion
Individualized RCC cell vaccines offer the possibility to
target immune responses to a unique array of epitopes that
arise through genetic mutation in tumor cells; however, a
parallel compensation must be made to improve the inferior
immune-stimulatory capacity of tumor cells. Today, prepa-
ration of patient-individualized tumor vaccines entails ob-
taining tumor samples from individual patients, genetically
engineering them under stringent GMP conditions, and
performing quality assurance studies to demonstrate that
sufficient numbers of cells show adequate levels of gene
expression to achieve the desired immune effects. Combined,
all of these steps require substantial amounts of time, result
in high costs, and yield potential limitations in vaccine
availability for individual patients, particularly if multiple
vaccine applications with large numbers of cells are deemed
to be beneficial.
Our vaccine strategy was designed to overcome these lo-
gistical hurdles by relying on the use of a generic vaccine that
could be applied in multiple patients. For vaccine develop-
ment, we used a well-characterized RCC-26 tumor cell line
that showed strong immunogenic potential in extensive
preclinical studies (Schendel and Gansbacher, 1993; Schendel
et al., 1993, 2000; Frankenberger et al., 2005a,b). This inherent
immune-stimulatory potential was improved through gene
modification to allow the RCC-26 cells to express surface
CD80 molecules in order to improve their capacity to induce
T cell responses through provision of secondary activation
signals to responding lymphocytes. This strategy was sup-
ported by our preclinical experimental mouse tumor models,
which clearly demonstrated that CD80 expression on tumor
cells induced cytotoxic T lymphocytes by direct priming
(Cayeux et al., 1997). Furthermore, CD80 expression on RCC-
26 cells supported reactivation of effector memory T cells
that were present in patients with RCC (Schendel et al., 2000).
Gene modification of RCC-26 cells to secrete IL-2 was
chosen because of the well-known clinical benefits of IL-2
achieved in some patients with RCC by systemic therapy
(Rosenberg, 2007). Our vaccine cells secreted only low levels
of IL-2 (8 ng of IL-2 per 106 cells per 24 hr) and thus systemic
effects were not expected. In fact, it was shown previously
that the amount of IL-2 produced by vaccine cells has a
strong impact on the generation of tumor immunity. If vac-
cine cells released high amounts of IL-2, tumor immunity
could be completely abrogated (Schmidt et al., 1995). Our
preclinical studies of IL-2-modified RCC-26 cells showed
clearly that low levels of IL-2 could indeed specifically sup-
port activation of effector memory cells. This was mani-
fested in the remobilized effector lymphocytes by increased
Table 3. Absolute Numbers of Peptide-Reactive T Cells in Peripheral Blood (per 1.5105 Cells
Pre=postvaccination)
ID DTH Pool Ba Pool Db Survivin Cyclin D1 ADFP c-Met
Time to progression
(weeks)
Survival
(weeks)
MR-1 þ 44=66c 93=59 –=–d 12=– 25=– 49=– 7 31
MR-2 þ 27=140e 11=33 56=51 71=15 20=85 34=65 23 79
MR-4 þ 95=101 54=54 14=62 28=38 46=76 29=72 35 68
MR-5 þ 51=124 17=33 –=25 –=33 –=35 –=47 7 76
MR-6f – –=19 –=– 14=– 13=– 14=– 35=– 6 18
MR-7f þ 39=173 –=41 16=– –=– –=– –=– 28 84
MR-9f þ 34=44 29=34 18=– 12=– –=11 12=14 39 79
MR-10 þ 97=104 71=75 81=– –=15 43=23 20=– 23 55
MR-11 þ 141=150 75=171 –=29 –=– –=– –=– SD (7)g 17
MR-13 þ 98=114 108=161 –=12 –=– 34=– 20=– 33 104 (alive)
MR-14 þ 13=75 –=24 17=32 –=59 –=35 –=19 35 107
MR-15 þ –=57 –=41 –=26 24=30 –=25 19=24 SD (131)g 151 (alive)
Abbreviations: DTH, delayed-type hypersensitivity reaction; SD, stable disease.
aPool B contains the peptides for RGS-5, apolipoprotein, MUC-1, OFA, hTERT, and KIAA0367 (PRUNE2).
bPool D contains the peptides for VEGF, NY-ESO, Her2=neu, MAGE-1, 3, 6, and WT-1.
cThe values represent absolute numbers of spots for pre- and postvaccination (pre=post) responses. These values are given after subtraction
of background responses (i.e., without peptide or with irrelevant Bcr=Abl peptide). The highest postvaccination response is given irrespective
of the time point postvaccination (i.e., at 6, 14, 22, or 36 weeks).
dNo values mean no reactivity (10 Spots above background, which corresponds to a frequency of 1=1.5104 IFN-g-secreting peptide-
specific T cells).
eValues representing a greater than 2-fold increase in reactivity against the peptides post-versus prevaccination are indicated in bold. With
the larger peptide pools a reactivity of 40 spots above background was considered positive.
fShort protocol of vaccination starting with the middle dose of 107 vaccine cells.
gSD (7) and SD (131) indicate stable disease at weeks 7 and 131, respectively.
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proliferation, enhanced cytotoxic function against tumor
cells, and improved survival through upregulation of anti-
apoptosis genes in the remobilized effector lymphocytes
(Frankenberger et al., 2005b). Furthermore, IL-2 expression
by the vaccine cells supported the activation of natural killer
cells (Schendel and Gansbacher, 1993).
Moreover, the vaccine cells could further impact the de-
velopment of immune responses through their capacity to
induce alloresponses due to expression of mismatched HLA
allotypes with study patients, providing a rich cytokine mi-
lieu as well as nonspecific help through recruitment of CD4þ
T cells that could support the development of antitumor
immunity (Schendel et al., 2000). We showed previously
that ongoing alloresponses stimulated by the vaccine cells
did not suppress T cell responses to RCC-associated epitopes
(Frankenberger et al., 2005a).
Because this was a generic vaccine designed for use in
patients who expressed the HLA-A*0201 allotype, only one
vaccine development phase was needed. This allowed ex-
tensive characterization of the vaccine cells postproduction
according to GMP standards to certify that the genetically
engineered cells presented excellent characteristics with re-
spect to gene expression and immunological function
(Frankenberger et al., 2005a). Thereafter, there were no
time constraints for patient use and the amount of vaccine
was not a limiting factor. The vaccine cells were available in
an irradiated, cryopreserved formulation that allowed direct
application to patients without manipulation after thawing.
The clinical status of the patient was the primary factor that
influenced the number of vaccine applications that could be
delivered during the study period.
Because only one tumor cell line was employed, it was
also possible to carry out extensive studies regarding ex-
pression of a variety of TAAs in the vaccine cells. This al-
lowed the identification of a series of TAAs that were
overexpressed in RCC-26 cells and made it possible to devise
specific immune-monitoring tools to study the induction or
reactivation of TAA-specific T cells. Surrogate peptides, re-
presenting epitopes derived from several overexpressed
TAAs, were selected for their capacity to be presented by
HLA-A2 molecules. They were tested either in pools or as
single peptides to measure T cell responses in patients
throughout the study course. This enabled several parame-
ters of response to be assessed, providing a better picture of
the development of specific immune responses generated
through vaccination in the study group.
This form of tumor cell vaccination was found to be fea-
sible and safe. The designated vaccine course was completed
in 9 of 15 patients. Despite heavy tumor burdens at study
entry, seven patients completed a vaccination schedule
spanning 22 weeks. The majority of patients had multiple
metastases at two or more sites at enrollment, and more
than half of the patients had poor prognosis scores according
to Palmer and colleagues (1992), revealing their advanced
states of disease. Those patients who progressed too rapidly
to complete the vaccine protocol had poor prognosis
scores of 2 or 3, according to the criteria of Palmer and
colleagues.
The vaccine was also determined to be safe, even when
applied at doses of 40106 cells. Although vaccine site re-
actions and DTH challenge reactions increased in magnitude
with increasing vaccine applications, this did not prohibit
10 vaccine applications in the course of 22 weeks. These
responses were transient, disappeared within a few days,
and did not require medical intervention. The most serious
vaccine-associated toxicity was the transient increase in
amylase and lipase enzyme levels in four patients. These
increases were first detected after the fifth vaccine injection.
They increased during the subsequent vaccine applications
given at 2-week intervals but then disappeared, despite
further increases in cell dose. Thus, these transient increases
seemed to be related more to the time interval between
vaccine applications than to cell dose. These increases were
not accompanied by other systemic symptoms and signs of
pancreatitis were not detected by clinical examination, im-
aging, and measurement of additional blood parameters.
Development of autoimmunity was assessed by the ap-
pearance of anti-nuclear antibodies and rheumatoid factor or
changes in complement factors. No relevant changes were
noted in any patient throughout the study course.
All patients had progressive disease before they entered
the study, except one patient (MR-14) who was enrolled
previously in a peptide vaccine trial (A. Buchner, unpub-
lished observation). Of the 14 progressing patients, half
showed stable disease for time periods ranging from 23 to
131 weeks. The median time to progression was 5.3 months
and the median tumor-specific survival time was 15.6
months. Interestingly, studies of much larger groups of pa-
tients showed progression-free survival times of 5.5 months
with the angiogenesis inhibitor sorafenib (Escudier et al.,
2007) and 5 months with IFN-a (Motzer et al., 2007); how-
ever, the side effects of these therapies were much greater.
Progression was detected at various sites and new lesions
appeared in various organs. It should be noted that although
13 patients had lung metastases at study entry, further tumor
progression at this site was observed in only 1 patient (MR-
4). In addition, the progression of multiple lung lesions in
this patient was slow. It has been observed in other studies
that lung metastases may respond better to immunother-
apies than metastases at other sites (Han et al., 2003).
Immune monitoring revealed that vaccine-induced T cell
responses could be detected in a majority of the patients.
Strong reactivity to the control viral CEF pool was detected
in prevaccination samples of all evaluated patients, indicat-
ing that their memory T cells were capable of responding to
antigenic stimulation despite extensive tumor burden that is
often associated with a general state of immune suppression
(Frankenberger et al., 2007). Responses to CEF peptides were
retained in seven of nine patients postvaccination at 22
weeks. However, spot numbers were lower in three patients
at 36 weeks compared with values obtained at weeks 1, 6,
and 14, indicating some loss of immune potential. There
were also surprisingly high responses to vaccine lysates in
the prevaccination samples and these increased in nine pa-
tients through vaccination. Because the responding lym-
phocytes in the ELISPOT assays were not separated into
natural killer (NK) and T cell fractions, it is possible that
some of this reactivity was due to NK cells, which were
shown previously to respond to RCC-26 cells in the presence
of IL-2 (Schendel et al., 2000; Falk et al., 2002; Frankenberger
et al., 2005b). On the other hand, there is substantial evidence
that patients with RCC spontaneously develop T cell re-
sponses to their tumors. Thus, some of the response to lysate
stimulation may reflect responses of effector memory T cells.
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Because RCC-26 cells overexpress a large number of various
TAAs, such T cell responses may be specific for TAAs that
are shared by various RCCs. Further evidence of the pres-
ence of preexisting effector memory T cells in some patients
was reflected in the ELISPOT responses detected to the pools
and single peptides in prevaccine PBMCs.
More than half of the patients showed vaccination-
associated increases in T cell reactivity to surrogate peptides
that were derived from TAAs overexpressed by the vaccine
cells and commonly shared by RCC (Stevanovic, 2002). The
patterns of response to the single peptides and peptide pools
were diverse, indicating that an immunodominant epitope
was not present in this set of surrogate peptides. Further-
more, several patients responded to two or more specific
peptides or pools, indicating that several epitopes expressed
by the vaccine cells could elicit ELISPOT responses in these
patients with advanced disease. However, no correlation was
found between degree of immune response and stabilization
of disease as reflected by time to progression or survival
times. Further studies are needed to elucidate the individual
specificity of responses occurring to the two peptide pools.
This will then provide a more complete picture of the spec-
ificity and complexity of T cell responses, including the role
of epitope spreading, occurring as a result of vaccination.
Although no clinical responses according to RECIST were
detected, the median survival time seen in this small patient
group was long, considering their clinical status at study
entry. Because of the minimal side effects, vaccination was
well tolerated and could be delivered on an outpatient basis
throughout the study course. The use of a generic vaccine
strategy for selected HLA-A*0201-positive patients contrib-
uted substantially to the feasibility of employing an escalat-
ing, multidose vaccine strategy because vaccine cells were
not limiting. This generic approach also allowed a stan-
dardized immune-monitoring approach to be used for all
study patients. On the basis of the preliminary results pre-
sented here, it can be concluded that the majority of patients
acquired increased T cell reactivity through vaccination to
several epitopes derived from shared TAAs. Such T cell re-
sponses may be able to elicit significant immune attacks
against autologous tumor lesions in better clinical settings.
This could include, for example, combining vaccination with
the application of treatment strategies that reduce regulatory
cells that can dampen ongoing immune responses. Further-
more, combination therapies employing vaccination and
new molecular inhibitors to block tumor-driven angiogenesis
and retard tumor progression may allow better immune re-
sponses to develop over longer periods of time.
The demonstrated feasibility of applying this vaccine in a
group of patients at fairly low cost, with substantial savings
in time and logistics as compared with individualized pa-
tient vaccines—alongside safety, low toxicity, and substan-
tial immune-stimulatory potential—supports performing
further evaluations of this vaccine in combination therapies
and as adjuvant therapy in patients with minimal residual
disease.
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